Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031668 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP3A4KMT2AMEN1F2 | |
| SCHEMBL6029390 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP3A4KMT2AMEN1F2 | |
| SCHEMBL1720259 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP3A4KMT2AMEN1F2 | |
| SCHEMBL15055075 | 0.84 | HSPB1 (0.55) | HSPB1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL15911431 | 0.81 | HSPB1 (0.71) | HSPB1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL4481437 | 0.80 | MEN1 (0.68) | HSPB1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL28203192 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP3A4KMT2AMEN1TSHR | |
| SCHEMBL15053944 | 0.78 | F2 (0.55) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1718988 | 0.77 | MAPT (0.68) | SMN1; SMN2CYP3A4KMT2AMEN1TSHR | |
| SCHEMBL22687000 | 0.77 | TSHR (0.49) | SMN1; SMN2CYP3A4KMT2AMEN1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1503986-A4 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | claimed |
| EP-1503986-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| WO-2003059258-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2013096153-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096151-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-27 | — | — | WO | disclosed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1503986-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059258-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | HSPB1 187/4885SMN1; SMN2 633/4885CYP3A4 4768/4885 |
| US-20060173024-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | HSPB1 187/4885SMN1; SMN2 633/4885CYP3A4 4768/4885 |
| US-20050148638-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | HSPB1 187/4885SMN1; SMN2 633/4885CYP3A4 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.